The kinin system mediates hyperalgesia through the inducible bradykinin B1 receptor subtype: evidence in various experimental animal models of type 1 and type 2 diabetic neuropathy.

Abstract

Both insulin-dependent (type 1) and insulin-independent (type 2) diabetes are complex disorders characterized by symptomatic glucose intolerance due to either defective insulin secretion, insulin action or both. Unchecked hyperglycemia leads to a series of complications among which is painful diabetic neuropathy, for which the kinin system has been implicated. Here, we review and compare the profile of several experimental models of type 1 and 2 diabetes (chemically induced versus gene-prone) and the incidence of diabetic neuropathy upon aging. We discuss the efficacy of selective antagonists of the inducible bradykinin B1 receptor (BKB1-R) subtype against hyperalgesia assessed by various nociceptive tests. In either gene-prone models of type 1 and 2 diabetes, the incidence of hyperalgesia mostly precedes the development of hyperglycemia. The administration of insulin, achieving euglycemia, does not reverse hyperalgesia. Treatment with a selective BKB1-R antagonist does not affect basal nociception in most normal control rats, whereas it induces a significant time- and dose-dependent attenuation of hyperalgesia, or even restores nociceptive responses, in experimental diabetic neuropathy models. Diabetic hyperalgesia is absent in streptozotocin-induced type 1 diabetic BKB1-R knockout mice. Thus, selective antagonism of the inducible BKB1-R subtype may constitute a novel and potential therapeutic approach for the treatment of painful diabetic neuropathy.

• Authors: Bichoy H Gabra, Nathalie Berthiaume, Pierre Sirois, François Nantel, Bruno Battistini
• Journal: Biological chemistry (Biol Chem) Vol. 387 Issue 2 Pg. 127-43 (Feb 2006) ISSN: 1431-6730 [Print] Germany
• PMID: 16497144 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Anticonvulsants
• Bradykinin B1 Receptor Antagonists
• Receptor, Bradykinin B1

Topics

• Animals
• Anticonvulsants (therapeutic use)
• Bradykinin B1 Receptor Antagonists
• Diabetes Mellitus, Type 1 (drug therapy, epidemiology, metabolism)
• Diabetes Mellitus, Type 2 (drug therapy, epidemiology, metabolism)
• Diabetic Neuropathies (drug therapy)
• Disease Models, Animal
• Humans
• Hyperalgesia (drug therapy, metabolism)
• Kallikrein-Kinin System (physiology)
• Receptor, Bradykinin B1 (deficiency, metabolism)